Ludwig Institute Oncology Unit and Tumor Targeting Program, Austin Health Trials

Ludwig Institute Oncology Unit and Tumor Targeting Program, Austin Health	Welcome, Profile Billing Logout

Ludwig Institute Oncology Unit and Tumor Targeting Program, Austin Health

Welcome, Profile Billing Logout

5 Trials

8 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Scott, Andrew

ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed

300

Europe, Canada, US, RoW

89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)

Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd

Clear Cell Renal Cell Carcinoma

10/22

11/22

PROSTACT, NCT04876651: The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Recruiting

392

RoW

177Lu-DOTA-rosopatamb, 177Lu-TLX591, Standard of Care

Telix Pharmaceuticals (Innovations) Pty Ltd

Metastatic Prostate Cancer

11/25

12/28

iPREDICT, NCT05013099 / 2021-005610-33: Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

Active, not recruiting

Europe, US, RoW

zirconium Zr 89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C

ImaginAb, Inc.

Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma, Non Small Cell Lung Cancer

07/25

I-FIRST, NCT05182931: A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer ( Study)

Recruiting

RoW

Dabrafenib 75 MG, Tafinlar, Trametinib 2 MG, Mekinist

Olivia Newton-John Cancer Research Institute, Royal North Shore Hospital, Austin Health, Sir Charles Gairdner Hospital, Monash Health, Peter MacCallum Cancer Centre, Australia, Royal Brisbane and Women's Hospital, Eastern Health, The Alfred, Royal Adelaide Hospital

Thyroid Cancer

12/24

12/25

NCT06909825: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Active, not recruiting

RoW

FPI-2265, Olaparib

Fusion Pharmaceuticals Inc.

Metastatic Castration-resistant Prostate Cancer

01/30

08/30

NCT04721756: Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging

Recruiting

RoW

18F-LY3546117 Injection, PET Scan

Avid Radiopharmaceuticals

Neoplasms, Neoplasms Malignant

04/24

NCT05868174: Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Recruiting

RoW

89Zr-TLX250, 89Zr-DFO-girentuximab, 177Lu-TLX250 and Peposertib, 177Lu-DOTA-girentuximab

Telix Pharmaceuticals (Innovations) Pty Limited, Merck KGaA, Darmstadt, Germany

Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma

12/24

12/26

NCT04127981: Medical Imaging of Cachexia

Recruiting

N/A

RoW

18F-FDG PET + Dexa Scan

Olivia Newton-John Cancer Research Institute, La Trobe University, Austin Health

Cancer Cachexia

12/23

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Scott, Andrew

ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed

300

Europe, Canada, US, RoW

89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)

Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd

Clear Cell Renal Cell Carcinoma

10/22

11/22

PROSTACT, NCT04876651: The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Recruiting

392

RoW

177Lu-DOTA-rosopatamb, 177Lu-TLX591, Standard of Care

Telix Pharmaceuticals (Innovations) Pty Ltd

Metastatic Prostate Cancer

11/25

12/28

iPREDICT, NCT05013099 / 2021-005610-33: Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

Active, not recruiting

Europe, US, RoW

zirconium Zr 89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C

ImaginAb, Inc.

Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma, Non Small Cell Lung Cancer

07/25

I-FIRST, NCT05182931: A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer ( Study)

Recruiting

RoW

Dabrafenib 75 MG, Tafinlar, Trametinib 2 MG, Mekinist

Thyroid Cancer

12/24

12/25

NCT06909825: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Active, not recruiting

RoW

FPI-2265, Olaparib

Fusion Pharmaceuticals Inc.

Metastatic Castration-resistant Prostate Cancer

01/30

08/30

NCT04721756: Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging

Recruiting

RoW

18F-LY3546117 Injection, PET Scan

Avid Radiopharmaceuticals

Neoplasms, Neoplasms Malignant

04/24

NCT05868174: Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Recruiting

RoW

89Zr-TLX250, 89Zr-DFO-girentuximab, 177Lu-TLX250 and Peposertib, 177Lu-DOTA-girentuximab

Telix Pharmaceuticals (Innovations) Pty Limited, Merck KGaA, Darmstadt, Germany

Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma

12/24

12/26

NCT04127981: Medical Imaging of Cachexia

Recruiting

N/A

RoW

18F-FDG PET + Dexa Scan

Olivia Newton-John Cancer Research Institute, La Trobe University, Austin Health

Cancer Cachexia

12/23

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites